Advertisement

Advertisement
Breast Cancer

T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or -Ultralow Metastatic Breast Cancer

The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has been approved by the U.S. Food and Drug Administration...


Lung Cancer

Anatomic Lung Resection May Be Linked to Improved Survival in Early-Stage NSCLC

Anatomic lung resections such as lobectomy and segmentectomy may be associated with improved long-term survival...

Colorectal Cancer

Novel Combination Targeted Therapies, Chemotherapy in BRAF-Mutated Metastatic Colorectal Cancer

First-line treatment with the targeted therapies encorafenib and cetuximab plus a modified leucovorin, fluorouracil, and oxaliplatin...


Advertisement
Colorectal Cancer

New Findings on Aspirin and Risk of Colorectal Cancer Recurrence

According to one of the first biomarker-driven randomized study in people with nonmetastatic colorectal cancer, taking 160 mg of aspirin daily...

Colorectal Cancer

New Research Explores Blood Test to Determine Prognosis, Benefit of Celecoxib in Stage III Colon Cancer

Previous research has shown that nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin and COX-2 inhibitors...

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Breast Cancer

Some Patients With Low-Risk Ductal Carcinoma In Situ May Be Able to Avoid Surgery

Active monitoring appears to be a safe strategy for the management of some patients with low-risk ductal carcinoma in situ (DCIS), proving noninferior to guideline-concordant management of this patient population (ie, surgery with or without radiation therapy). After 2 years, the rate of invasive...

Advertisement

FDA Approves Mirdametinib for Neurofibromatosis Type 1

On February 11, the U.S. Food and Drug Administration approved mirdametinib (Gomekli), a kinase inhibitor, for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. ReNeu Trial...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Multiple Myeloma

AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma

Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...

Lung Cancer

Getting a Lung Cancer Diagnosis Was Shocking

For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...

Dual Immunotherapy Extended Progression-Free Survival in Metastatic Colorectal Cancer Subgroup

An immunotherapy combination for advanced, highly mutated colorectal cancer has significantly delayed disease progression vs single-agent therapy, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.1 The phase III CheckMate 8HW trial compared the PD-1 inhibitor...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

2.83% Medicare Physician Reimbursement Cut Finalized for 2025; Estimated 4% Cut for Medical Oncology

Late in 2024, the Centers for Medicare & Medicaid Services (CMS) issued the 2025 Physician Fee Schedule (PFS) final rule adopting changes for Medicare payments under the PFS. CMS also released the 2025 Hospital Outpatient Prospective Payment System final rule, which sets hospital outpatient...

Advertisement

Mobile Prostate Cancer Screening Clinic Was Effective in Detecting Prostate Cancer in Underserved Men

Globally, prostate cancer is the second most frequently diagnosed cancer and the fifth-leading cause of cancer-related death among men—and the leading cause of cancer-related death in Central America and sub-Saharan Africa. Four years ago, British researchers launched the “Man Van” pilot mobile...

ASCO Post X Feed
Social Media Hub by Everwall